This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): EDP-01
Description: BL-6010 is a small molecule, enzymatically-stable purine receptor agonist that promotes insulin secretion in the presence of glucose by a novel mechanism. Animal models demonstrated that BL-6010 reduces high blood glucose levels thus having potential as a therapeutic treatment for type 2 diabetes.
Deal Structure: BL-6010 is being developed by BioLineRx under a worldwide exclusive license from Bar Ilan Research and Development Company (BIRAD).
Additional information available to subscribers only: